Exchange Announcement • 14 Sep 2026 15:00
U.S. Fda Accepts New Drug Application Under Priority Review For Takeda’S Zasocitinib In Moderate-To-Severe Plaque Psoriasis
Exchange Announcement • 29 Aug 2026 08:30
Takeda Receives U.S. Fda Approval Of Mimrylo (Rusfertide) , Marking A Potential Shift In The Treatment Paradigm For Polycythemia Vera
Exchange Announcement • 06 Aug 2026 07:00
U.S. Fda Approves Takeda’S Orzeyful (Oveporexton) , The First And Only Medicine To Treat The Underlying Cause Of Narcolepsy Type 1
Exchange Announcement • 30 Jul 2026 14:30
Earnings Report (Kessan Tanshin) For The Three-Month Period Ended June 30, 2026 (Ifrs, Consolidated)
Exchange Announcement • 08 Jul 2026 14:30